RTI Surgical™ Announces First Implantation of map3™ Cellular Allogeneic Bone Graft in a Foot and Ankle Procedure

  RTI Surgical™ Announces First Implantation of map3™ Cellular Allogeneic Bone
  Graft in a Foot and Ankle Procedure

Business Wire

ALACHUA, Fla. -- September 25, 2013

RTI Surgical Inc. (RTI) (Nasdaq:RTIX), a global surgical implant company, is
pleased to announce the first implantation of the company’s map3™ Cellular
Allogeneic Bone Graft implant in a foot and ankle procedure.

Dr. Michael Lyons, DPM, an associate member of the American College of Foot
and Ankle Surgeons, performed the implantation during a medial column fusion
procedure in Indiana. He used the implant’s chips allograft configuration, one
of two configurations that will be available.

“Taking into account the published MAPC™ research, I decided to use map3 in a
complex case with an immune-compromised patient because it would support the
patient’s ability to heal,” said Dr. Lyons. “I was impressed by the ease of
use – it required very little time to prepare with simple instructions for
preparation. I will definitely use map3 again when it’s appropriate for the
patient’s case.”

Map3 cellular allogeneic bone graft is a natural and safe alternative to
autograft. Map3 provides a streamlined approach to bone grafting and supplies
the three elements necessary for bone repair—osteogenesis, osteoinduction and
osteoconduction — in a single allograft. Map3 incorporates multipotent adult
progenitor cell-based (MAPC-based) technology with stem cells isolated from
the same donor as the other bone material. The MAPC technology, licensed from
Athersys, Inc. for this orthopedic application, represents a distinctive type
of stem cell with recognized angiogenic and immuno-modulatory properties. Map3
will be available in multiple configurations and sizes, providing bone
grafting options for various bone repair, reconstruction and fusion
procedures.

“Dr. Lyons’ successful use of map3 in a foot and ankle procedure is an
exciting new development following its use in spine procedures,” said Brian K.
Hutchison, RTI president and CEO. “The MAPC-based technology offers the
greatest potential to create high quality, innovative implants for our
surgeons and their patients and will greatly enhance our company’s
orthobiologics offerings. We anticipate a limited market release of the
implant later this year.”

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons
with safe biologic, metal and synthetic implants. Committed to advancing
science, safety and innovation, RTI’s implants are used in sports medicine,
general surgery, spine, orthopedic, trauma and cardiothoracic procedures and
are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla.,
and has four manufacturing facilities throughout the U.S. and Europe.RTI is
accredited in the U.S. by the American Association of Tissue Banks and is a
member of AdvaMed. For more information, please visit www.rtix.com.

Forward-Looking Statement

This communication contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management’s current expectations, estimates and
projections about our industry, our management's beliefs and certain
assumptions made by our management. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," variations of such words
and similar expressions are intended to identify such forward-looking
statements. In addition, except for historical information, any statements
made in this communication about anticipated financial results, growth rates,
new product introductions, future operational improvements and results or
regulatory actions or approvals or changes to agreements with distributors
also are forward-looking statements. These statements are not guarantees of
future performance and are subject to risks and uncertainties, including the
risks described in public filings with the U.S. Securities and Exchange
Commission (SEC). Our actual results may differ materially from the
anticipated results reflected in these forward-looking statements. Copies of
the company's SEC filings may be obtained by contacting the company or the SEC
or by visiting RTI's website at www.rtix.com or the SEC's website at
www.sec.gov.

Contact:

RTI Surgical Inc.
Jenny Highlander, APR, 386-418-8888
Manager, Corporate Communications
jhighlander@rtix.com